Figure 1 showed that serum prokineticin-2 levels were significantly elevated in participants with MS than those without MS (7.72 ± 3.34 vs 5.56 ± 2.39 ng/ml, P < 0.001). Here, PROK2 is linked to myeloid sarcoma.